Roche pipeline includes several potential blockbusters likely to enter Ph III testing
11 February 2008
Kosan opens Ph II study of alvespimycin
28 January 2008
GSK's Tyverb gets nod from CHMP
24 December 2007
HERmark assay identifies best Herceptin responders
24 December 2007
Neoadjuvant Xeloda reduces breast tumor size in Ph II trial
24 December 2007
Breast cancer market set to reach $2.9B in 2013, but still no cure
12 November 2007
Japan stock market week to Oct 29, 2007
5 November 2007
Herceptin clears HER2 tumors in 3x more women than chemo
8 October 2007
US biogenerics mart to reach $2B by 2016
17 September 2007
Belgium's drug spending "well under control"
10 September 2007
Oncologists reluctant to switch to Tykerb
20 August 2007
ImmunoGen gets $5M milestone
6 August 2007
Cancer, RA drugs boost Genentech
16 July 2007
UK's ABPI "admonishes" Bayer, GSK and Roche
16 July 2007
UK's NICE blamed for poor cancer care
21 May 2007
Roche 1st-qtr at top end of expectations
23 April 2007
GSK submits lapatinib NDA in Japan
9 April 2007
Three new drugs get nod from EMEA's CHMP
2 April 2007
Clarification to FDA's Tykerb approval
26 March 2007
Genentech updates of Cabilly patent re-examination
26 February 2007
Roche posts record 2006 net profits, boosted by cancer drugs
12 February 2007
Bavarian Nordic gets FDA OK to start breast cancer vacc trial
15 January 2007
Roche/Genentech
15 January 2007
Arimidex plus Herceptin improve survival in co-positives
22 December 2006
Herceptin/Taxotere improve DF survival
22 December 2006
Generex's cancer vacc well-tolerated
22 December 2006
November a lackluster month for biotechnology stocks, says Burrill
18 December 2006
Japan stock market week to Dec 4, 2006
11 December 2006
Herceptin availability in UK is paid for by "dropped" patients
4 December 2006
BMJ defends UK's NICE legal challenge
4 December 2006
Herceptin gets FDA ok for HER2 node
27 November 2006
Roche reports sales of $23.89B for first three qtrs of 2006, a 4.7% share of global market
23 October 2006
Roche submits Herceptin to EMEA for new HER2(+) indication
23 October 2006
Genentech's 3rd-qtr GAAP net leaps 58%
16 October 2006
Less price flexibility, more innovation: the market dynamics of targeted therapeutics
16 October 2006
FDA to review Tykerb as breast cancer therapy
25 September 2006
Israeli basket update c'tee recommends another 16 new technologies
4 September 2006
Israeli NHI Ombudswoman's complaints report
4 September 2006
UK's NICE issues final guidance on Herceptin
28 August 2006
Kosan selects names for its lead Hsp90 drugs
28 August 2006
UK's NICE rejects cancer drug, ponders Herceptin
7 August 2006
Australia negotiates on Roche's Herceptin
31 July 2006
Herceptin appeal against NICE approval
17 July 2006
UK's NICE appeal, consultation deadline
3 July 2006
Japan stock market week to June 19, 2006
26 June 2006
Personalized medicine - reality or just an illusion?
19 June 2006
UK's NICE Herceptin ruling takes two weeks
19 June 2006
GSK's Tykerb 'to rival Herceptin,' Ph III study
12 June 2006
Stock Commentary - Europe - week to May 29, 2006
5 June 2006
Roche's Herceptin OK for early use in EU, CHMP
29 May 2006
Australia to control doctors' gifts/perks
29 May 2006
Roche's 1st-qtr 2006 sales rise 22%
8 May 2006
NICE says inhaled insulin "too expensive" for UK, Pfizer appeals to health professionals
24 April 2006
Strong in vitro data for GPC Biotech's satraplatin
10 April 2006
GPC presents promising data at AACR
10 April 2006
US FDA accepts NDAs from Genentech, Eisai, GSK and S-P
20 February 2006
Herceptin: judge OKs "postcode lottery"
20 February 2006
Test case for Herceptin to decide if UK health providers can refuse breast cancer drug treatment
13 February 2006
Kosan starts trials of KOS-1022 and KOS 953 in cancer therapy
30 January 2006
Kosan's KOS-953 plus Herceptin to enter Ph II
19 December 2005
Herceptin for early-stage use in Australia soon?
19 December 2005
Licensing pivotal to pharma industry evolving strategies
19 December 2005
Protein test may aid advanced cancer therapy
5 September 2005
Canadian provinces OK Genentech's Herceptin
1 August 2005
UPDATE: UK NICE fast-track of Herceptin welcomed
1 August 2005
UK fast-tracks Velcade, Herceptin through NICE
25 July 2005
Roche Rx sales grow three times world rate
25 July 2005
Stock Commentary - Europe
23 May 2005
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
